Sagent Pharmaceuticals Launches National Research Center in Chengdu, China

Sagent Pharmaceuticals Launches National Research Centerin Chengdu, China

SCHAUMBURG, Ill., Feb. 3, 2014 (GLOBE NEWSWIRE) -- Sagent
Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty
pharmaceutical products with a specific emphasis on the injectable
market, today announced the launch of its National Research Center
("NRC") in Chengdu, China. Based in Chengdu's Bio-Technology Park, the
NRC will focus on process and method development of technically
challenging specialty injectable pharmaceuticals.

Staffed with an international team of experienced research scientists,
the center will initially focus on developing both liquid and
lypholization products for Sagent China Pharmaceuticals ("SCP"),
Sagent's FDA-inspected manufacturing facility, also located in Chengdu.

"Building a first class development center in support of our
manufacturing capabilities is a natural next step in our strategic
evolution," said Jeffrey M. Yordon, chief executive officer and
chairman of the board of Sagent. "The NRC is equipped with
state-of-the-art equipment and staffed with a team of global experts in
specialty injectable development. We are proud of the progress of our
team in China and pleased to provide increased support for the rapid
development of additional products to be manufactured at SCP."

About Sagent Pharmaceuticals

Sagent Pharmaceuticals, Inc., founded in 2006, is a specialty
pharmaceutical company focused on developing, manufacturing, sourcing
and marketing pharmaceutical products, with a specific emphasis on
injectables. Sagent has created a unique, global network of resources,
comprising rapid development capabilities, sophisticated manufacturing
and innovative drug delivery technologies, resulting in an extensive
and rapidly expanding pharmaceutical product portfolio that fulfills
the evolving needs of patients.


CONTACT: SAGENT CONTACT:
        Jonathon Singer
        [email protected]
        (847) 908-1605

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.